Clinical Trial Update: Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN [Phase 3]

View source ↗

Summary

Phase 3 trial update on iptacopan for C3 glomerulopathy and immune-complex-mediated membranoproliferative glomerulonephritis; recruitment is ongoing to assess l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• C3 Glomerulopathy
• Immune Complex-mediated Membranoproliferative Glomerulonephritis

Drugs mentioned

• iptacopan (iptacopan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis | Phase 3 | Status: RECRUITING